HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP

被引：0
|
作者：
Muggiano, A. [1 ]
Mulas, C. [1 ]
Fiori, B. [1 ]
Liciardi, G. [1 ]
Pintus, M. [1 ]
Tanca, L. [1 ]
Tedde, A. [1 ]
Turno, R. [1 ]
Desogus, A. [1 ]
机构：
[1] Osped Oncolog A Businco, Div Med Oncol 1, Cagliari, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [11] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
    Muggiano, A
    Mulas, C
    Fiori, B
    Liciardi, G
    Pintus, M
    Tanca, L
    Tedde, A
    Turno, R
    Desogus, A
    MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7
  • [12] The role of interferon alfa-2b adjuvant therapy of high risk resected melanoma stage I & II.
    Economou, GK
    Koletsis, EN
    Filopoulos, E
    PROCEEDINGS EUROSURGERY 2000, 2000, : 141 - 144
  • [13] TREATMENT PATTERNS OF ADJUVANT INTERFERON ALFA-2B (IFN-α2B) FOR HIGH-RISK MELANOMA. A RETROSPECTIVE STUDY OF THE GRUPO ESPAnOL MULTIDISCIPLINAR DE MELANOMA (GEM)
    Martin-Algarra, S.
    Soriano, V.
    Malvehy, J.
    Berrocal, A.
    Quindos, M.
    Martinez Del Prado, P.
    Soria, A.
    Marquez-Rodas, I.
    Palacio, I.
    Cerezuela, P.
    Alonso, L.
    Lopez-Vivanco, G.
    Nocea, G.
    Stevinson, K.
    Del Barrio, P.
    Tornamira, M. V.
    Guillem Porta, V.
    Espinosa, E.
    ANNALS OF ONCOLOGY, 2014, 25
  • [14] Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b
    Fluck, M
    Kamanabrou, D
    Lippold, A
    Reitz, M
    Atzpodien, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (03) : 280 - 289
  • [15] Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
    Grossmann, Kenneth F.
    Othus, Megan
    Patel, Sapna P.
    Tarhini, Ahmad A.
    Sondak, Vernon K.
    Knopp, Michael, V
    Petrella, Teresa M.
    Truong, Thach-Giao
    Khushalani, Nikhil, I
    Cohen, Justine, V
    Buchbinder, Elizabeth, I
    Kendra, Kari
    Funchain, Pauline
    Lewis, Karl D.
    Conry, Robert M.
    Chmielowski, Bartosz
    Kudchadkar, Ragini R.
    Johnson, Douglas B.
    Li, Hongli
    Moon, James
    Eroglu, Zeynep
    Gastman, Brian
    Kovacsovics-Bankowski, Magdalena
    Gunturu, Krishna S.
    Ebbinghaus, Scot W.
    Ahsan, Sama
    Ibrahim, Nageatte
    Sharon, Elad
    Korde, Larissa A.
    Kirkwood, John M.
    Ribas, Antoni
    CANCER DISCOVERY, 2022, 12 (03) : 644 - 653
  • [16] LONG-TERM ADJUVANT THERAPY OF HIGH-RISK MALIGNANT-MELANOMA WITH RECOMBINANT INTERFERON ALFA-2B
    KOKOSCHKA, EM
    TRAUTINGER, F
    MISCKSCHE, M
    KOKOSCHKA, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 560 - 560
  • [17] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [18] Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U. K.
    von der Maase, H.
    Brandberg, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [19] Acute rhabdomyolysis associated with administration of high-dose interferon alfa-2b for high-risk melanoma
    Ramirez, A. Vanegas
    Fischer, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 50 - 50
  • [20] Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies
    Kirkwood, JM
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S12 - S17
12345